Navigation Links
BioMS Medical's phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
Date:10/3/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Oct. 3 /PRNewswire-FirstCall/ - BioMS Medical Corp. (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the independent Data Safety Monitoring Board (DSMB) for the Company's U.S. pivotal phase III MAESTRO-03 trial of dirucotide (MBP8298) in patients with secondary progressive MS has completed a safety analysis and recommended that the trial continue as per the protocol.

This was the third of several regularly scheduled reviews by the DSMB that will occur over the duration of the trial. The purpose of the DSMB is to provide objective, independent safety monitoring of the trial.

About MAESTRO-03

----------------

The MAESTRO-03 U.S. pivotal phase III clinical trial is a randomized, double-blind study that has completed recruitment of approximately 510 patients at 68 clinical sites who will be administered either dirucotide (MBP8298) or placebo intravenously every six months for a period of two years. The primary clinical endpoint for the trial is defined as a statistically and clinically significant increase in the time to progression of the disease as measured by the Expanded Disability Status Scale (EDSS), in patients with HLA-DR2 and/or HLA-DR4 immune response genes (up to 75% of all MS patients are HLA-DR2 and/or HLA-DR4 positive).

About BioMS Medical Corp.

-------------------------

BioMS Medical is a biotechnology company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivotal phase III clinical trials for secondary progressive MS patients, MAESTRO-01 in Canada and Europe and MAESTRO-03 in the United States. It additionally is being evaluated for relapsing remitting MS patients in a Phase II trial in Europe entitled MINDSET-01. In December 2007
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... , April 1, 2015  Adaptive Biotechnologies ... The Lancet Oncology showing that ... company,s next-generation sequencing-based minimal residual disease (MRD) detection ... MRD test) accurately identifies patients with diffuse large ... relapse after initial treatment, usually several months before ...
(Date:4/1/2015)... 01, 2015 Park Systems, ... selected to receive the prestigious “Best Analytic Instrumentation ... NX10 is the premium research-grade True Non-Contact AFM, ... linearity, closed-loop detector noise, and minimized thermal drift. ... n, which allows images with a single click, ...
(Date:4/1/2015)... /PRNewswire/ - Portage Biotech Inc. ("Portage") (OTC Market: ... announce that Biohaven Pharmaceutical Holding Company Limited (Biohaven), ... an agreement with inVentiv Health for the operational ... lead compound (BHV-0223). Biohaven is ... stage neuroscience compounds targeting the glutamatergic system. Clinical ...
(Date:4/1/2015)... FORT LAUDERDALE, Fla. , April 1, 2015 /PRNewswire/ ... nothing at all about oral cancer (68 percent) and ... at their last dental check-up, according to findings from ... Inc. ("Vigilant"), a leading innovator and developer of ... of cancer. The online survey polled 1,050 ...
Breaking Biology Technology:Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 2Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 3Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 4Adaptive Biotechnologies' clonoSEQ Minimal Residual Disease Test Predicts Relapse in Diffuse Large B-Cell Lymphoma Patients by Sensitively Detecting Circulating Tumor DNA 5Park Systems Awarded the New Economy Magazine “Best Analytic Instrumentation Company 2014” 2Portage's Biohaven Announces Agreement with inVentiv Health 2Portage's Biohaven Announces Agreement with inVentiv Health 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 2National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 3National Oral Cancer Awareness Survey Reveals Greater Need for Education and Screening Tools for Oral Cancer Among U.S. Adults 4
... of our nation,s long-term clean-energy future, but the technology ... Japan,s recent Fukushima disaster. Indeed, many nations have called ... are operating safely. In the United States, ... percent of the electricity from emission-free sources, including renewable ...
... Mediabrands, IPG Media Lab and Affectiva today announced, ... results of the first annual Neuromarketing Awards. Utilizing ... record and measure viewers, tacit, non-verbal response to ... features are established and are then measured and ...
... ,   The randomised, ... efficacy and safety of,the monoclonal antibody rituximab (RTX) ... that in patients with,severe AAV a single course ... period of 18 months proved to be as ...
Cached Biology Technology:Berkeley scientists pioneer nanoscale nuclear materials testing capability 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 2The IPG Media Lab and Affectiva Announce Winners of First Annual Neuromarketing Awards 3ERA-EDTA Congress 2011: Late Breaking Clinical Trials I 2
(Date:3/30/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/lc9bnl/global_gesture ) has ... Market in Automotive Sector 2014-2018" report to their ... Recognition market in Automotive Sector to grow at a ... Gesture recognition is the ability of a device to ... Gesture recognition technology can be 2D-based or 3D-based. It ...
(Date:3/24/2015)... 24, 2015   NexID Biometrics LLC, whose ... needs, today announced the beginning of shipments of version ... The company, based in Potsdam, N.Y. ... Connect:ID Expo, which began here today at the Walter ... 2.0 of its SDK boosts the accuracy rate range ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
... closely associated with the African savanna -- fierce lions, ... players when it comes to shaping the ecosystem. ... be the termite, say ecologists who,ve found that these ... Kenya via a network of uniformly distributed colonies. Termite ...
... study finds heterotrophic bacteria counts, in more than 70 ... specified by the United States Pharmacopeia (USP). Researchers ... 110th General Meeting of the American Society for Microbiology ... water a large number of urban Canadians are switching ...
... animals most closely associated with the African savanna -- ... relatively minor players when it comes to shaping the ... to be the termite, say ecologists who,ve found that ... central Kenya via a network of uniformly distributed colonies. ...
Cached Biology News:The star of Africa's savanna ecosystems may be the lowly termite 2The star of Africa's savanna ecosystems may be the lowly termite 3Study finds high level of bacteria in bottled water in Canada 2Lowly termite, not the lion or elephant, may be the star of Africa's savanna 2Lowly termite, not the lion or elephant, may be the star of Africa's savanna 3
... (Intein Mediated Purification with an Affinity Chitin-binding ... engineered protein splicing elements (termed inteins) to ... column (1-4) (Figures 1 and 2). This ... systems by its ability to separate a ...
... Analysis Note: The kit contains all ... convenient determination of NADPH-cytochrome c reductase activity ... purified microsomes [endoplastic reticulum (ER)]. It has ... tissues such as liver, kidney, brain, spleen, ...
... provides the reagents to efficiently differentiate ... myotubes. By efficiently promoting myogenic differentiation, ... in studies examining myogenesis, transcription factor ... muscle cell replacement therapy. By providing ...
... CHEMICON's Cell Transformation Detection Assay is an ... is considered the most stringent assay for ... this assay, cells (pre-treated with carcinogens or ... in soft agar medium for 21-28 days. ...
Biology Products: